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CObjectives: To demonstrate how value of information (VOI) analysis
can be used to establish research priorities regarding the use of phar-
macogenetic tests using CYP2D6 testing to select adjuvant hormonal
therapy in early stage breast cancer as a case study. Methods: The
following four treatment pathways are compared in a Markov model:
tamoxifen treatment; CYP2D6 test and treat homozygous and
heterozygouswild type patients (wt/wt; wt/*4) with tamoxifen and *4/*4
patients with anastrozole (HetTam); CYP2D6 test and treat homozy-
gous wild type patients with tamoxifen and others with anastrozole
(HomTam); and anastrozole treatment. Pharmacogenetic testing effi-
cacy is estimated by synthesizing randomized controlled trial data
comparing tamoxifen to anastrozole with observational data linking
CYP2D6 genotype to tamoxifen outcomes. Results: In order of increas-
ing effectiveness the comparators are tamoxifen, HetTam, HomTam,
anastrozole. Health outcomes for test and treatment strategies are
highly uncertain. Differences in comparator costs depend on assump-
tions made regarding anastrozole patent expiry. The expected value of O
Seac
al So
oi:10.1016/j.jval.2011.05.048a decision taken with perfect information is £69 to £106 million
(pound sterling) for the United Kingdom depending on patent expiry
assumptions and the acceptable cost-effectiveness threshold. The
most valuable research (VOI £53–£82million) elucidates the relation-
ship between CYP2D6 genotype and tamoxifen effectiveness. It is
uncertain whether values of other research designs would exceed
their costs. Conclusions: Retrospective analysis of one of the large
adjuvant aromatase inhibitor trials is warranted to better understand
any association between CYP2D6 genotype and tamoxifen outcomes.
OI approaches may be helpful for prioritising evidence needs and
tructuring coverage with evidence development agreements for phar-
acogenetics.
eywords: CYP2D6, decision modeling, pharmacogenetics, tamoxifen,
alue of information.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
A paucity of clinically relevant supporting evidence for pharma-
cogenetic tests has been identified as a limiting factor for inclusion
of pharmacogenetic information in drug labels [1] and the uptake
of pharmacogenetic testing [2]. This lack of clinically relevant ev-
idence is attributable to the regulatory environment for diagnos-
tics, test pricing dynamics, and the difficulties of designing trials
of biomarker-based treatment strategies.
The divergence between regulator and payer evidence require-
ments for pharmaceuticals is well documented [3]. For pharmaco-
genetic tests and other diagnostics this divergence is exacerbated
because regulatory approval does not require direct evidence of
clinical benefit from a randomized controlled trial (RCT). Instead,
regulators of diagnostics in the United States and the European
Union focus on test analytic validity (accuracy and consistency
of genotype detection) and to a lesser extent clinical validity
(accuracy of phenotype prediction) [4,5]. In addition, reimburse-
ment systems for diagnostics are currently not value based
[1,6,7]. For example, in the United States new tests are reim-
bursed based on their technical similarity (in terms of effort and
* Address correspondence to: Beth Woods, Oxford Outcomes Ltd.,
E-mail: beth.woods@oxfordoutcomes.com.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.complexity) to existing tests [1]. Thus, evidence of improved
patient outcomes is not reflected in a higher reimbursed price.
This lack of regulatory and reimbursement incentives to pro-
duce clinically relevant supporting data is compounded by the
difficulties of designing adequately powered trials for bio-
marker-based treatment strategies [8].
The result is a limited evidence base with which to assess
clinical utility (the net balance of health risks and benefits as-
sociated with using a test in routine practice) and economic
value (the balance of net health outcomes against cost) that
form the basis for efficient allocation of health care resources.
To facilitate timely uptake of pharmacogenetic tests, a number
of bodies have recommended coverage with evidence develop-
ment agreements [9,10]. These agreements make reimburse-
ment conditional upon further data collection, which is then
used to re-appraise the decision [11]. However, clear guidance
regarding the methods that should be used to determine when
additional research is warranted and what form this research
should take is lacking.
In this context, decision analysis allows us to explicitly and
quantitatively address key payer questions regarding clinical util-
ourt Tower, West Way, Botley, Oxford OX2 0JJ.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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990 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 8 9 – 1 0 0 1ity [12], economic value [7], and the uncertainty around these.
sing the example of CYP2D6 testing to guide adjuvant breast can-
er treatment, we report howdecisionmodeling alongwith formal
alue of information (VOI) methods can also be used to directly
valuate the potential value of future research.
Our example evaluates pharmacogenetic testing as a strategy for
reatment selection in postmenopausal womenwith early estrogen-
eceptor–positive breast cancer who have undergone surgery. This
xample is pertinent because of the potential health impact, uncer-
ainty surrounding recommendations for pharmacogenetic testing,
nd ongoing research efforts to establish the genotype–phenotype
ssociation. The analysis takes a United Kingdom decision-maker
erspective, though the disease model developed could be used as
he basis for evaluations in other jurisdictions.
For this patient group, hormonal therapy is recommended to
educe risk of recurrence. Previously the hormonal therapy of
hoicewas 5 years of tamoxifen; recently the aromatase inhibitors
anastrozole, exemestane, and letrozole) have been recommended
n the United Kingdom due to their increased efficacy and accept-
ble cost-effectiveness [13]. Emerging clinical evidence suggests
hat a further treatment pathway, whereby hormonal therapy se-
ection is determined by patient genotype, could be considered.
The cytochrome P450 (CYP450) metabolic enzyme CYP2D6 has
major role in tamoxifen metabolism [14] and is known to vary
mong individuals. The hypothesis is that plasma levels of endox-
fen (the most abundant active tamoxifen metabolite) and clinical
utcomes among patients administered tamoxifen are related to
atients’ CYP2D6 genotype [15]. The availability of a commercial
est kit for the CYP2D6 genotype (AmpliChip CYP450, Roche Diag-
ostics, Basel, Switzerland) and laboratory developed testing ser-
ices mean that use of pharmacogenetic testing to select hor-
onal therapy is a viable treatment pathway.
The evidence base for the genotype–phenotype association,
owever, is contested. A recent systematic review identified 15
tudies in the adjuvant setting [16] and concluded that there was
o consistent association between the CYP2D6 polymorphism and
amoxifen outcomes, with studies differing in both the direction
nd formal statistical significance of their results. The authors
dentify small sample sizes, poor analytical methods, and hetero-
eneity in the definitions of CYP2D6 genotype derivedmetabolizer
ategories as limiting factors in evaluating the association.
The uncertainty around the genotype–phenotype association
nd absence of evidence regarding clinical utility has generally
esulted in recommendations against uptake of the test [14,17,18].
his has included a decision by the US Food and Drug Administra-
ion (FDA) not to includeCYP2D6 testing guidance in the tamoxifen
abel, despite advisory committee support [19]. In Europe, the
harmacovigilenceWorking Party has recommended that labeling
nformation should highlight the “possible reduction in response to
amoxifen in poor CYP2D6 metabolisers” [20]. It remains to be seen
hether thiswill be implemented by themember states, including
he United Kingdom where CYP2D6 testing is currently not used
idely outside of research [21].
We evaluate the use of the AmpliChip CYP2D6 test assuming
hat following testing, treatment choice is based solely on the
resence or absence of the *4 allele, as this allele has been most
ommonly studied as a determinant of tamoxifen outcomes [16].
s patient genotype is determined by two alleles, three different
enotypes are possible using a *4-only based classification: wild-
ype (wt)/wt; wt/*4 and *4/*4, where wt refers to alleles other than
4. AmpliChip queries 26 CYP2D6 alleles of approximately 100
nown polymorphisms [22]. The *4-defined treatment pathways
epresent only a fraction of those possible with AmpliChip.
aboratory tests (e.g. Taqman, pyrosequencing, Roche Diagnos-
ics, Basel, Switzerland) could be used as an alternative to
mpliChip. These tests have different allele coverage and a dif-
erent set of associated feasible treatment pathways.Our analysis does not aim to provide a definitive recommen-
ation regarding use of CYP2D6 testing to determine treatment
hoice. Instead, by using decisionmodeling, we provide estimates
ased on currently available evidence of the comparative effec-
iveness and cost-effectiveness of pharmacogenetic testing, the
evel of uncertainty around these estimates, and whether and
hat type of additional research should be conducted to support
uture decision making.
Methods
The decision model takes a UK National Health Service (NHS) per-
spective. The health outcomes of interest are 5-year recurrence-
free survival (RFS) and lifetime quality-adjusted life years (QALYs).
The results of the study are relevant to white patients due to the
racial composition of the main clinical studies [23,24]. All patients
are assumed to be recurrence free and 65 years old on entry in to
the model, which is in line with the key clinical trials. Costs are in
2007 United Kingdom pound sterling (£).
Synthesizing RCT and observational evidence to estimate
comparative efficacy
Evidence from an RCT comparing anastrozole to tamoxifen (the
ATAC trial [23]) is synthesized with observational data comparing
tamoxifen efficacy across the CYP2D6 genotypes wt/wt, wt/*4, and
*4/*4 (Goetzandcolleagues [24]) to estimate the relativeefficacyof the
pharmacogenetic testing and drug treatment pathways.
Themodel focuses on the aromatase inhibitor anastrozole due to
the richnessofdataavailable fromtheATACtrial [23].ATAC is a large
(n  6241) double-blind RCT. A recent systematic review [25] identi-
ed ATAC as the only RCT of anastrozole in the primary adjuvant
etting and the largest trial of an aromatase inhibitor in the adjuvant
etting.
The Goetz study [24] analyzes data from 171 patients enrolled
n the tamoxifen arm of the phase III North Central Cancer Treat-
ent Group RCT of tamoxifen compared to tamoxifen plus flu-
xymesterone in the adjuvant setting (NCCTG 89-30-52) [26]. The
oetz study re-analyzes 12 years of outcome data by CYP2D6 me-
tabolizer categories. Themetabolizer categories are defined by pa-
tient CYP2D6 genotype and exposure to selective serotonin-re-
uptake inhibitors (SSRIs) – a class of drugs known to inhibit the
CYP2D6 enzyme and thought to affect tamoxifen outcomes. A re-
cent systematic review [16] identified three studies that examined
the association between *4 allele defined genotype categories and
breast cancer recurrence for patients receiving the 5 year tamox-
ifen protocol [24,27,28]. Of these, Goetz [24] included the largest
number of patients and was the only study that used clinical trial
data and accounted for concomitant SSRI use.
The estimated RFS hazard ratios for patients receiving tamox-
ifen in the Goetz study [24] were 1.4 (95% confidence interval [CI]
0.68–3.05) for the comparison of wt/*4 with wt/wt genotypes and
3.2 (95% CI 1.37–7.55) for *4/*4 compared with wt/wt genotypes,
based on sample sizes of 115, 40, and 16 for the wt/wt, wt/*4, and
*4/*4 groups. The wt/wt, wt/*4, and *4/*4 labels used here refer to
the extensive, intermediate, and poor metabolizer groups re-
ported by Goetz [24]. Because these metabolizer classes are de-
fined by both genotype and SSRI exposure, use of these datamakes
two assumptions. First, the relative efficacy of tamoxifen across
metabolizer classes is representative of the relative efficacy of ta-
moxifen across genotype classes in the absence of SSRI adminis-
tration and, second, if pharmacogenetic testing was adopted, the
SSRIs would not be administered. The first assumption is difficult
to assess because the impact of SSRI co-administration on tamox-
ifen outcomes is not yet well quantified [29]. The second assump-
tion is likely to be valid because, if pharmacogenetic testing is
adopted, this will reflect confidence in the relationship between
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the concerns regarding SSRI co-administration.
Given this genotype classification, the following four treatment
pathways are relevant (Fig. 1):
● Tamoxifen treatment;
● CYP2D6 HetTam: CYP2D6 test and treat both homozygous and
heterozygous wild type patients (wt/wt and wt/*4) with tamox-
ifen and *4/*4 patients with anastrozole;
● CYP2D6 HomTam: CYP2D6 test and treat homozygous wild type
patients with tamoxifen and others with anastrozole;
Anastrozole treatment.
The genotype composition of the test population is estimated
rom a Swedish adjuvant breast cancer patient cohort, which in-
luded 68% wt/wt patients, 27% wt/*4 patients, and 5% *4/*4 pa-
ients (n  677) [28].
Estimates of comparative efficacy for anastrozole and tamox-
fen are available directly from the ATAC trial [23] in the form of
arametric Weibull RFS curves. Estimation of RFS curves for the
harmacogenetic testing comparators requires genotype-specific
FS estimates for patients receiving tamoxifen. These are esti-
ated by decomposing the ATAC genotypically unselected ta-
oxifen RFS curve into genotype-specific curves. This requires the
ssumption that the genotype composition and variation in RFS
cross genotypes in ATAC can be approximated by the Goetz data
nd that the proportional hazards assumption holds across geno-
ypes. The higher recurrence rates among *4 carriers will result in
change in the genotype composition of the recurrence-free pop-
lation over time. This is accounted for in the model by re-esti-
ating the genotype composition of the recurrence-free popula-
CYP2D6 
HetTam
CYP2D6 
HomTam
Anastrozole
Tamoxifen
Decision node
Chance node
Terminal node (patients e
Fig. 1 – Including pharmacogenion in each time period using the genotype composition at theeginning of the previous time period and the genotype-specific
ates of recurrence during the previous time period. These meth-
ds are similar to those used by Punglia et al. [30].
The clinical parameters used to estimate the comparative effi-
acy of the pharmacogenetic testing and drug only treatment
athways are presented in Table 1.
Extrapolating from surrogate to decision endpoints
Amodel is required to extrapolate from the different RFS rates (the
surrogate) to expected lifetime costs and QALYs (the decision end-
points). The disease process is modeled using a Markov approach.
The disease states, allowed transitions and parameterization of
the model, are similar to those used in previous models of adju-
vant hormonal therapy [31–33] and are depicted in Figure 2. The
Markov model simulates costs and QALYs for four cohorts: anas-
trozole treated, tamoxifen treated, wt/wt tamoxifen treated, and
wt/*4 tamoxifen treated. Costs and QALYs associated with the
pharmacogenetic testing pathways are then calculated by weight-
ing the cohort-specific estimates by the genotype composition of
the test population and including test-related costs for all pa-
tients.
Due to an absence of evidence, the model assumes that the
following parameters do not vary between patients with different
CYP2D6 genotypes: aromatase inhibitor efficacy and safety, ta-
moxifen safety, and tamoxifen recurrence type composition. Ta-
moxifen may well be associated with more frequent adverse
events and an improved recurrence type profile in patients better
able tometabolize the drug. The net direction of the impact of this
assumption on the model results is therefore uncertain.
In line with previous models, patients follow the RFS curves
Tamoxifen
Tamoxifen
Tamoxifen
Anastrozole
Tamoxifen
Anastrozole
Anastrozole
wt/wt
 Markov process)
Anastrozole
P2D6 
test
P2D6 
test
wt/*4
*4/*4
wt/wt
wt/*4
*4/*4
testing in the comparator set.nter
CY
CY
eticdescribed above for years 1 to 5, for years 6 to 15 all patients follow
G992 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 8 9 – 1 0 0 1the tamoxifen RFS curve (i.e., no difference in RFS according to
drug or genotype is assumed). This may be conservative with re-
spect to the effectiveness and therefore cost-effectiveness of both
the CYP2D6 testing and anastrozole pathways. Evidence from the
oetz study [24] suggests that the hazard of recurrence on tamox-
ifen may differ between metabolizer classes up to year 10. Evi-
dence from ATAC suggests that the hazard of recurrence may dif-
fer between tamoxifen and anastrozole up to year 8 [34]. For years
16 and onwards all patients are assumed to experience recurrence
in line with incident rates in the general population [35]. The re-
currence type composition (contralateral, locoregional, andmeta-
static) is estimated using data from ATAC [23,36], transition prob-
abilities beyond the initial recurrence are estimated using
observational data [37–39]. The clinical parameters used to extrap-
olate from RFS to the decision endpoints are provided in Table 2.
The following adverse events are included in the model because
they exhibited statistically significant differences in incidence be-
tween the tamoxifen and anastrozole arms of ATAC and were ex-
pected to have important cost or quality of life implications: vaginal
bleeding, endometrial cancer, spinal fractures, ischemic cerebrovas-
cular (IC) events, and deep vein thromboembolic (DVT) events. The
event rates and themethods and data used to calculate cost,mortal-
ity, and quality of life implications of these adverse events are pro-
vided as a data supplement. Supplemental material accompanying
this article can be found at 10.1016/j.jval.2011.05.048.
Table 1 – Clinical parameters used to estimate comparative
Parameter
Weibull parameters* – ATAC recurrence-free
survival curve (see also Fig. 3)
In
S
A
Hazard ratios for recurrence across genotypes w
*4
Genotype composition in Goetz cohort w
w
*4
Genotype frequencies in test population w
w
*4
ATAC, arimidex, tamoxifen, alone or in combination trial; 95% CI, 95
* SAS parameterization of Weibull distribution.
Contralateral 
disease Yr1 
Locoregional 
recurrence 
Yr1 
Disease free 
survival +/- 
adverse event 
Fig. 2 – Modeling from recurrence-free survival to decision e
shown). Yr1, year 1; Yr2+, year 2 and beyond.Utility data was taken from Lidgren et al. [40]. A previous sys-
tematic review of utility data in breast cancer [41] identified this as
the only study reporting utility values for relevant health states
thatwere derived by administering a generic quality-of-life instru-
ment to patients and valuing their responses using a general pop-
ulation based tariff, in line with UK decision-maker preferences
[42]. The estimates are based on EuroQol five-dimensional ques-
tionnaire health profiles elicited from 17 to 177 patients (depend-
ing on health state) attending breast cancer outpatient appoint-
ments at the Karolinska University Hospital, Sweden, in April and
May 2005. These data are presented in Table 3.
Costs are incurred with CYP2D6 testing and administration,
hormonal therapy acquisition and administration, and time spent
in each breast cancer health state [43–46]. The cost of a delivered
test result is estimated to be £395 (personal communication,
Adrian Smith, Roche Diagnostics, June 13, 2008). Patients who
were disease free while on treatment were assumed to attend an
annual oncology outpatient visit andmammogram as per existing
models [45]. Patients were assumed to require an additional on-
cologist appointment for communication of CYP2D6 test results
and discussion of treatment. Resource use estimates for the post-
recurrence health states were estimated based on a sample of 199
early breast cancer patients who relapsed between 1991 and 2004
at theWestern General Hospital, Edinburgh, and covered resource
use related to surgery, radiotherapy, chemotherapy, hormonal
cacy.
imate ([variance] or
[95% CI–, CI])
Source
pt  9.172 (0.00533) ATAC trial (Hind [31];
0.831 (0.00098) Mansel [32] for data)
ozole  0.249 (0.00439)
s. wt/wt  1.4 (0.68–3.05) Goetz [24]
s. wt/wt  3.2 (1.37–7.55)
 67% (115/171) Goetz [24]
23% (40/171)
9% (16/171)
 68% (460/677) Wegman [28]
27% (183/677)
5% (34/677)
fidence interval.
Metastatic 
disease 
Breast 
Cancer Death 
Contralateral 
disease Yr2+ 
Locoregional 
recurrence 
Yr2+ 
ints (death from all causes possible from all states, noteffi
Est
terce
cale 
nastr
t/*4 v
/*4 v
t/wt
t/*4 
/ *4 
t/wt
t/*4 
/*4 
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atients are assumed to receive hormonal therapy for 5 years or
ntil breast cancer recurrence.
At the time of the analysis, the patent for anastrozole is ex-
ected to expire in February 2011 in the UK [47], all analyses are
herefore presented for two scenarios, the first assumes the price
f anastrozole will be held at the prevailing level (“patent price”
cenario) and the second estimates that the anastrozole price will
Table 2 – Clinical parameters used to extrapolate from recu
Parameter type
Recurrence probability, tamoxifen years 15 Age 80–84: 0.3
Age 85: 0.43
Recurrence composition on tamoxifen Contralateral
Locoregional
Metastatic 
Treatment effect of anastrozole on recurrence
(yrs 1-5 only)
Contralateral
Locoregional
Metastatic HR
Probability metastatic given contralateral /
locoregional recurrence
0.72 (10 year p
Median survival if metastatic 17.8 months (
All-cause mortality Age dependen
ATAC, arimidex, tamoxifen, alone or in combination trial; HR, hazard
Table 3 – Utility (quality of life) and cost parameters.
Parameter Esti
Disease-free survival (year 1) – receiving
hormonal therapy
0.744 (95% CI 0.5
Disease free survival (year 2) – receiving
hormonal therapy
0.824 (95% CI 0.7
Contralateral/locoregional recurrence
(year 1)
0.779 (95% CI 0.7
Contralateral/locoregional recurrence
(year 2)
0.779 (95% CI 0.7
Metastatic recurrence 0.685 (95% CI 0.6
AmpliChip delivered result (cost for
laboratory to analyze blood sample
including AmpliChip device, labor,
controls, and consumables)
£
Consultant appointment to discuss
pharmacogenetic test results
Tamoxifen (generic) 20 mg once daily
(20 mg  30 pack)
Anastrozole (arimidix) 1 mg once daily
(1 mg  28 pack)
£68.56 (£12.34 for
Annual cost disease-free survival £
Contralateral tumor (year 1) £15,
Locoregional tumor (year 1) £11,
Contralateral tumor (year 2) £
Locoregional tumor (year 2) £1,
Distant metastases £5,
Terminal care £4,
Costs given in pound sterling (£).
NHS, National Health Service.fall by 82% when generics are introduced (“generic price” sce-
nario), based on the experience in New Zealand [48]. The costs
estimates used in the model are provided in Table 3.
A time horizon of 35 years is used in the model to generate
lifetime cost and health outcome estimates. A 1 year cycle length
is used and a half cycle correction is applied. Costs and health
outcomes are discounted at 3.5% per annum in line with the stip-
ulations of UK decision makers [42].
ce free survival to decision endpoints.
mate Source
UK National statistics [35]
/420 AstraZeneca [36]; ATAC [23]
/420
20
0.48 (SE ln(RR): 0.24)
0.75 (SE ln(RR): 0.15)
84 (SE ln(HR): 0.09)
bility) (n  140) Kamby and Sengelov [37]
46) Chang [38]
Government Actuary’s Department
[39]
; RR, relative risk; SE, standard error of the mean.
Source
.841) Lidgren [40]
.857)
.849)
.811)
.735)
Personal communication, Adrian Smith,
Roche Diagnostics, June 13, 2008.
NHS reference costs [43]. Cost codes
TCLFUMFF 103; TCLFUSFF 103; TCLFUMFF
800; TCLFUSFF 800 weighted by number of
attendances.
British National Formulary [44,54]
ric scenario) British National Formulary [44,54]
Sum of cost of consultant appointment (see
above) and mammogram – NHS reference
costs [43], cost code RA28Z.
Karnon [45] 2005 costs, inflated to 2007
values using UK health care inflation
indices [46].rren
Esti
8%
%
 54
 101
265/4
RR 
RR 
 0.
roba
n  3
tmate
73–0
85–0
00–0
45–0
20–0
395
£83.31
£3.07
gene
111.02
684
887
479
058
279
941
t
t
0
(
N
i
g
d
a
m
p
l
t
c
a
n
Q
l
t
a
b
u
m
l
t
v
t
s
i
l
m
p
t
Q
t
a
t
s
s
o
(
a
w
m
b
a
e
t
(
i
£
p
g
a
h
994 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 8 9 – 1 0 0 1Estimating uncertainty
Uncertainty is quantified in the decision model by assigning dis-
tributions to all parameters that are subject to sampling uncer-
tainty. This joint uncertainty in the parameter inputs is then prop-
agated through the model via Monte Carlo simulation. A
multivariate normal distribution is assigned to the Weibull pa-
rameters describing the ATAC RFS curves; Dirichlet distributions
are assigned to genotype prevalence estimates for the test and
ATAC populations and to the composition of recurrence type; log-
normal distributions are assigned to all hazard ratio and relative
risk parameters; beta distributions to the probability of progres-
sion from contralateral/locoregional to metastatic disease, the
probability of death from metastatic disease, the utility parame-
ters and the proportions used in resource use calculations; and
gamma distributions for aggregate costs, unit costs and resource
use estimates.
The parameterization of each distribution can be derived from
the data presented in Tables 1, 2, and 3 with the following excep-
ions. For the multivariate normal distribution the following addi-
ional parameters are required: covariance (intercept, scale) 
.00185; covariance (intercept, coefficient)  –0.00134; covariance
scale, coefficient)  0.00028 (personal communication, Enrico de
igris, Double Helix, October 2, 2008). For the cost data, limited
nformation regarding sampling uncertainty is available. For ag-
regate costs wemade the conservative assumption that the stan-
ard error is equal to half of the mean. Where separate unit cost
nd resource use estimates are used, standard errors for the for-
er are based on the assumption that the interquartile range re-
orted in UK reference costs [42] represents a 50% CI and for the
atter are set equal to half the mean values.
Drug costs, the cost of testing, population-based parameter es-
imates (all-cause mortality; post–15-year recurrence), and dis-
ount rates are not subject to stochastic uncertainty and are not
ssigned probability distributions.
Estimating the value of research
The expected value of perfect information (EVPI) is estimated. EVPI
provides an estimate of the expected value of eliminating all un-
certainty relating to the decision. Although an unattainable goal,
this gives the upper bound on the expected value of further re-
search. Therefore, any research designwith costs in excess of EVPI
should not be undertaken [49].
EVPI is estimated for each decision threshold by calculating the
et benefit distribution associated with the simulated cost and
ALY pairs. For each simulation, the cost of uncertainty is calcu-
ated as the difference between the net benefit of the technology
hat offers themaximumnet benefit for that particular simulation
nd the expected net benefit of the technology thatmaximizes net
enefit on average across all simulations [50]. Averaging this
across simulations and multiplying by the number of patients ex-
pected to benefit from the information generates the EVPI esti-
mate. The number of patients expected to benefit from the infor-
mation in the UK is estimated as the discounted sum of a 10-year
stream of 22,781 incident cases per annum [31].
The expected value of having perfect information about partic-
lar groups of parameters (expected value of partial perfect infor-
ation [EVPPI]) is also calculated. This requires two simulation
oops [51]. The outer loop involves randomly sampling (750 itera-
ions) from the parameter group of interest; the inner loop in-
olves, for each outer loop simulation, randomly sampling from
he remaining parameters (1000 iterations). For each outer loop
imulation the net benefit of the intervention that offers the max-
mum expected net benefit across inner loop simulations is calcu-
ated. This is then averaged across outer loop simulations to esti-
ate the net benefit associatedwith perfect information about the
arameter group of interest. Subtraction of the expected net ben- aefit associated with the most cost-effective technology based on
current information then generates the EVPPI. Again, this is mul-
tiplied by the total number of patients expected to benefit from the
information.
For the EVPPI calculations parameters were grouped according
to the type of study required to obtain further data on them.
● Genotyping studies was split into two components: the first
aimed to provide further information on genotype prevalence
in the test population, which could be achieved using a cross
sectional study; the second was to provide further information
on the genotype prevalence and difference in RFS across geno-
types used to decompose the ATAC tamoxifen RFS curve,
which would require a longitudinal study (e.g., a retrospective
association study using existing tamoxifen RCT data);
● RCT: would provide further information regarding recurrence
and adverse event probabilities for anastrozole and tamoxifen
(i.e., another ATAC-type trial);
● Costing study: would provide further information regarding
costs associated with breast cancer and adverse event states;
● Utility study: would provide further information regarding util-
ity weights associated with breast cancer and adverse event
states.
All analyses were implemented in R with the MASS andMCMC
packages installed [52] (R Foundation for Statistical Computing,
Vienna, Austria).
Results
Comparative effectiveness and cost-effectiveness
The genotype-specific RFS curves derived from synthesising the
observational and RCT data are presented in Figure 3. The model
predicts that wt/wt patients receiving tamoxifen perform almost
as well as patients receiving anastrozole. The wt/*4 and *4/*4 pa-
tients receiving tamoxifen exhibit poorer performance than geno-
typically unselected tamoxifen patients whose performance is
heavily influenced by the prevalent wt/wt genotype.
The associated mean 5-year RFS rates predicted by the model
for each treatment pathway are 87.3% for tamoxifen, 89.0% for
CYP2D6 HetTam, 90.2% for CYP2D6 HomTam, and 90.5% for anas-
rozole.
These differential recurrence rates drive the differences in
ALYs and health state costs across comparators (see Table 4). In
he patent price scenario, differences in costs across comparators
re driven by the proportion of patients receiving anastrozole in
he treatment pathway. The test cost does not drive results for this
cenario. The incremental cost per QALY results for this scenario
uggest that assuming an acceptable cost-effectiveness threshold
f £20 to £30,000/QALY (pound sterling), CYP2D6 HomTam
CYP2D6 testing followed by tamoxifen for wt/wt genotypes and
nastrozole for all others) would be the optimal treatment path-
ay. Although this is not quite the most effective comparator,
oving to themost effective comparator anastrozole is unlikely to
e considered good value as the marginal 0.012 QALY gain is
chieved at a cost of £2,081 with an associated incremental cost-
ffectiveness ratio of £177,096/QALY. The incremental cost-effec-
iveness ratio for the comparison of anastrozole with tamoxifen
£20,830/QALY) is within the range of findings of previous UK stud-
es that estimated incremental costs per QALY of £11,428 [45],
17,656 [32], and £31,965 [31]. Figure 4 presents the results of the
atent price analysis as a cost-effectiveness frontier. Under the
eneric price scenario, anastrozole dominates the other compar-
tors, and offers a marginally lower cost and the highest expected
ealth outcomes. In this scenario differences in treatment, test,
nd health state costs all drive the small differences in total costs.
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Depending on expectations regarding the generic anastrozole
price, a decision maker may consider adopting the CYP2D6
HomTamcomparator to replace the incumbent treatment (tamox-
ifen or anastrozole depending on the context). Estimates of the
uncertainty around the incremental health outcomes (QALYs
shown, 5-year recurrence rates display the same trends) and cost
of CYP2D6 HomTam relative to each treatment are presented as
simulations on the cost-effectiveness plane in Figure 5. Uncer-
tainty in total costs is relatively low, the main uncertainty is
around the likely price of anastrozole following patent expiry.
Uncertainty around health outcomes is high and is similar re-
gardless of the comparison as it is driven by uncertainty in
CYP2D6 HomTam efficacy and not uncertainty in drug treat-
ment efficacy which is relatively low. However, the nature of the
uncertainty depends on the comparator treatment. Compared
with tamoxifen, themodel predicts a high probability that phar-
macogenetic testing offers a health gain. Compared with anas-
trozole, CYP2D6 HomTam offers close to equal probabilities of
osses and gains in health outcomes. Cost-effectiveness accept-
bility curves, indicating the probability that each intervention
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Table 4 – Life year, QALY, and cost results for patent and g
Comparator Life years
(undiscounted)
QALYs
(discounted)
Testing
Tamoxifen 15.63 9.20 —
CYP2D6 HetTam 15.78 9.28 £479
CYP2D6 HomTam 15.90 9.35 £479
Anastrozole 15.92 9.36 —
Costs given in pound sterling (£).
ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life yes cost-effective across plausible cost-effectiveness thresholds,
re presented in Figure 6.
Value of further research
Results of the EVPI and EVPPI analyses are presented in Figure 7.
Based on a 10-year stream of 22,781 cases per annum, the EVPI
is estimated at £69 to £106 million depending on whether a
decision threshold of £20,000 or £30,000/QALY is assumed and
whether the expected reduction in anastrozole price is mod-
eled. This value is likely to exceed the costs of feasible research
designs, indicating that further research may be of value. The
EVPPI results suggest that the parameters that could be in-
formed by a longitudinal study relating CYP2D6 genotype to ta-
moxifen outcomes (i.e., a study that could estimate the geno-
type composition of the ATAC trial and the hazard ratios for RFS
across genotype subgroups) are associated with a research
value of £53 to £82million, which is likely to exceed the research
cost. These parameters could be informed by genotyping one of
the large trials comparing the aromatase inhibitors with tamox-
ifen (for example, the ATAC trial). It is less certain that the value
3 4 5
 in years
Anastrozole
Tamoxifen w t/w t
Tamoxifen
Tamoxifen w t/*4
Tamoxifen *4/*4
rence free survival curves.
ic price analyses.
Costs (discounted) ICER (£/QALY) vs.
comparator
(patent/generic)reatment
(patent/
generic)
Health
state
Total (patent/
generic)
£170 £6,646 £6,816 Reference/dominated
by anastrozole
£370 / £199 £6,385 £7,234 / £7,063 £4,774 vs. tamoxifen/
dominated by
anastrozole
1,442 / £355 £6,167 £8,088 / £7,001 £13,864 vs. CYP2D6
HetTam/dominated
by anastrozole
4,136 / £744 £6,033 £10,169 / £6,777 £177,096 vs. CYP2D6
HomTam/dominantime
ecurener
T
£
£ars.
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costs.
Interestingly, the EVPI and EVPPI for longitudinal genotyping
estimates are higher under the generic anastrozole price sce-
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Fig. 4 – Cost-effectiveness frontier for patent price analysis. CoFig. 5 – Uncertainty in efficacy and costs of CYP2D6 testing versunario than the patent price scenario when a £30,000/QALY ac-
ceptable cost-effectiveness threshold is assumed. Under the
patent price scenario the loss of value associated with choosing
CYP2D6 HomTam in the simulations where anastrozole offers
0.1 0.15 0.2
ALYs (vs. tamoxifen)
m vs. 
 = £13,864/QALY
rozole vs. CYP2D6 
am = £177,096/QALY
iven in pound sterling (£). QALYs, quality-adjusted life years.al Q
LY
mTa
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omT
sts gs incumbent treatments. Costs given in pound sterling (£).
997V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 8 9 – 1 0 0 1higher net benefit is limited by the high additional cost of choos-
ing the drug treatment pathway. Conversely, under the generic
price scenario where anastrozole is the cost-effective treat-
ment, the loss of value associated with choosing anastrozole in
the simulations where HomTam offers higher net benefit is
higher because there is little difference between strategies with
respect to cost. When a £20,000/QALY threshold is assumed, the
EVPI and EVPPI for longitudinal genotyping estimates are lower
under the generic scenario than the patent scenario. This re-
flects the reduced importance of uncertainty around health out-
comes relative to uncertainty around costs in determining the
Fig. 6 – Cost-effectiveness acceptability curves. (A) Patent an
pound sterling (£).VOI estimates for the lower threshold.Discussion
By applying decisionmodeling and VOI analysis to the example of
CYP2D6 testing to guide tamoxifen therapy, we have been able to
quantify the potential clinical utility and economic value of testing
based on current evidence, the uncertainty around these esti-
mates, and the value of further research. Both the clinical utility
and economic value of the test are highly uncertain, due to uncer-
tainties in the association between CYP2D6 genotype and tamox-
ifen outcomes, and due to uncertainties regarding the price trajec-
tory of anastrozole. The VOI analysis provides quantitative
zole price. (B) Generic anastrozole price. Costs given inastroguidance regarding research prioritization and indicates that fur-
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998 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 8 9 – 1 0 0 1ther research of the association between CYP2D6 genotype and
tamoxifen RFS is likely to represent a cost-effective use of health
care research resources. It is less clear that research on the geno-
type prevalence, relative drug effectiveness (RCT), utility, and cost
parameter groups would be cost-effective because the value of
research may not exceed the associated costs. Furthermore, it is
not clear whether the values associated with these research de-
signs would be maintained if further data collection was con-
ducted to reduce the uncertainty in the genotype-phenotype as-
sociation.
The VOI estimates presented are restricted to the value for the
United Kingdom. Because further data regarding the association
between CYP2D6 genotype and tamoxifen recurrence would likely
e considered relevant in a number of jurisdictions, the estimates
resented can be considered a lower bound to total (global) EVPPI.
urthermore, as the clinical uncertainties apply across jurisdic-
ions it is likely that the VOI estimates would exceed the cost of
esearch in many jurisdictions.
Study limitations
The current study is based on the NCCTG 89-30-52 trial data,
which found a statistically significant but highly uncertain asso-
ciation between the presence of the *4 allele and poorer tamoxifen
outcomes. Other studies of the *4 allele have produced conflicting
results. A recent review [16] identified two studies reporting co-
orts that exhibited a statistically significant association [24,53]
nd three which found statistically insignificant trends for im-
roved outcomes in carriers of the *4 allele [27,28,54]. All of these
tudies are small observational cohorts and only two controlled
or concomitant SSRI administration [24,53]. Use of these studies
nstead of the NCCTG 89-30-52 data or alongside it using evidence
ynthesis would produce different cost-effectiveness and VOI es-
imates. However, we would expect the VOI estimates to remain
igh as all studies report very uncertain outcomes.
The CYP2D6 testing treatment pathways included in the cur-
ent analysis represent all those possible using only the presence
f the *4 allele as a determinant of treatment choice. The review by
erasawa et al. [16] identified four studies in Caucasian popula-
ions, which examined the impact of additional alleles on tamox-
fen outcomes. These studies report outcomes in different sub-
roups defined by one or more of 22 genotypes. These genotypes
ould be used to define a very large number of possible alternative
Fig. 7 – Value of information estimates. Costs givenreatment pathways following CYP2D6 testing. Again, we would bxpect the VOI estimate to remain high if additional treatment
athways were included as there would bemore comparators and
he associations between genotype and outcomes in these studies
ere also very uncertain. Given the uncertainties in the current
vidence base it is also possible that other CYP2D6 genotypes or
ther biomarkers that better predict tamoxifen outcomes will be
dentified in the future.
Themodel is restricted to white patients due to the racial com-
osition of the key clinical studies. There is evidence to suggest,
owever, that CYP2D6 genotype may relate to tamoxifen out-
omes in other racial groups [55,56]. Further decision modeling
ork could be used to estimate the clinical utility of testing, the
conomic value of testing and the need for further research in
hese populations.
Themodel focuses on the aromatase inhibitor anastrozole due
o the richness of data available from the ATAC trial. Inclusion of
he other aromatase inhibitor licensed in the primary adjuvant
etting, letrozole, would be unlikely to dramatically alter the con-
lusions because it is associated with similar efficacy [25] and cost
31] as anastrozole. Further work would be required to confirm
his.
Costs of alternative CYP2D6 testing approaches, for example
espoke laboratory testing, would produce different estimates of
he cost-effectiveness of testing and value of further research. It is
ot expected that this wouldmarkedly alter the conclusions of the
nalysis because test cost is not a key driver of the model and the
ost of laboratory testing is thought to be similar to or lower than
he cost of AmpliChip [21].
The current analysis explores two possible scenarios regarding
he long-term price trajectory for anastrozole. It is quite possible
hat the timing of patent expiry and generic price for anastrozole
ill differ from the scenariosmodeled and thus impact on the VOI.
he scenarios modeled, however, do suggest that the value of fur-
her research to estimate the relationship between CYP2D6 geno-
ype and tamoxifen outcomes is likely to remain high.
Some of the assumptions made in the current model may not
e tenable, for example the assumption that tamoxifen safety and
ecurrence composition does not vary with CYP2D6 genotype,
hereas RFS does. These assumptions were made in the absence
f relevant data. We would not expect these assumptions to have
large impact on our results as overall recurrence is the key driver
n the model. A retrospective study examining the relationship
ound sterling (£). RCT, randomized controlled trial.in petween genotype and tamoxifen outcomes could also be used to
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999V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 8 9 – 1 0 0 1examine the relationship between recurrence type and genotype.
Understanding the relationship between genotype and adverse
event rates will be challenging due to the relatively low event
rates.
Implications
Payers, research commissioners, and regulators.Our analysis indicates
that there is likely to be a high societal value to retrospectively
genotyping one of the large trials comparing the aromatase inhib-
itors with tamoxifen. The two trials in the primary adjuvant set-
ting – ATAC [23] and BIG 1-98 [57] – were sponsored by the aroma-
tase inhibitor manufacturers AstraZeneca and Novartis.
Therefore, it is not clear that a test manufacturer could comply
with a “coverage with evidence development” or “only in re-
search” recommendation for CYP2D6 testing by a payer. Coverage
for testing with a requirement for prospective observational data
collection is plausible, butmay be of limited value as evaluation of
the genetic association would not be possible if women with a
variant genotype were not given tamoxifen. A plausible study de-
sign would be an RCT comparing testing versus no testing strate-
gies, but such a trialwould likely require a large sample size and be
expensive. Furthermore, even if this researchwas possible it is not
clear that it would produce a net benefit to the test manufacturer
because the device is relatively cheap and unlike patented phar-
maceuticals, it faces direct competition.
This raises the question of whether regulators or payers should
mandate the retrospective genotyping study. It could be argued that
this should be a condition for continued marketing approval for the
aromatase inhibitors because the association betweenCYP2D6 geno-
type and tamoxifen outcomes has important implications for the
aromatase inhibitor risk-benefit profile.With the pending patent ex-
piration of anastrozole, the financial incentives for such a mecha-
nism are limited. Thus, public funding to evaluate the validity of the
genetic association may be the most realistic scenario.
Interestingly, our analysis indicates that a prospective RCT
comparing testing to no testingmay not be themost cost-effective
research design. These findings both help clarify research priori-
ties but also inform the discussion of evidence thresholds for
pharmacogenetic tests from a regulatory, guideline, and reim-
bursement perspective.
Pharmaceutical industry. The current analysis clearly describes
the need to evaluate the full “test and treat” pathway in decision
models, rather than evaluating a drug in a genotype-defined sub-
group. That is, treatments and outcomes in patients who “test neg-
ative” need to be understood. This has important implications for
pharmaceutical companies operating in a value-based pricing envi-
ronment and deciding whether to target a particular genetic sub-
group. The genotype targeted indication evaluated as a subgroup
may appear to offer the potential for a much higher price than the
price feasible once the cost of genotyping all patients is incorporated.
Test developers. Decision modeling and VOI analysis should be
used by test developers as amethod of demonstrating the value of
their tests in terms of clinical and economic benefits and the value
of further clinical research. Decision modeling could also be used
to inform trial design by identifyingwhich test and treat strategies
should be included as comparators and whether a trial is likely to
be worthwhile (if the probability that testing is more effective or
cost-effective than standard care is very low a trial may not be
worth undertaking).
Areas for further research. Heterogeneity in the groupings of ge-
notypes across studies describing the genotype–phenotype asso-
ciationmakes evidence synthesis difficult. Evenwithin the studies
examining only the *4 allele, some studies reported results sepa-
rately for the wt/wt; wt/*4, and *4/*4 categories whereas others
grouped the wt/*4 and *4/*4 categories together. Although pre-
specification of the groups for comparison is important to avoid
researchers data dredging for statistically significant differences,reporting should also include separate results for each genotype
evaluated. This data could then be readily synthesized by applying
network meta-analysis methods currently employed to synthe-
size trials containing different comparator sets.
Conclusion
Our analysis suggests that retrospective analysis of one of the
large adjuvant aromatase inhibitor trials to better understand any
association between CYP2D6 genotype and tamoxifen outcomes
would represent a valuable use of health care research resources.
More generally, VOI approaches are likely to be helpful for priori-
tizing evidence needs and structuring coverage with evidence de-
velopment agreements for pharmacogenetics.
Postscript
Subsequent to completion of this work, preliminary results from
genotyping the ATAC and BIG 1-98 trials with the purpose of ex-
amining the association between CYP2D6 genotype and tamoxifen
outcomes were presented at the San Antonio Breast Cancer Sym-
posium in December 2010 [58–60].
CYP2D6 genotype data from ATAC were available for 588 and
15 patients randomized to tamoxifen and anastrozole, respec-
ively (13% of the trial population). Patients were genotyped for
he seven most common alleles that were then used to assign a
core based on predicted allele activities; potent CYP26 inhibitor
sage was controlled for. CYP2D6 genotype data from BIG 1-98
ere available for 4628 patients (58% of the trial population). Pa-
ients were defined as poor, intermediate, and extensive metabo-
izer categories based on their genotype. Both studies have re-
orted preliminary estimates of the association between expected
YP2D6 activity and breast cancer recurrence rates; however, nei-
her found evidence of a relationship based on the classifications
sed.
These preliminary findings suggest that CYP2D6 testing is un-
ikely to provide clinical utility or economic value in this context.
ull publication of these results and an assessment of the robust-
ess of the algorithm used to definemetabolizer classes will likely
etermine whether this is the last word on the CYP2D6-tamoxifen
tory.
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